Log In
Print
BCIQ
Print
Print this Print this
 

KRN23, UX023

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionRecombinant human IgG1 mAb against fibroblast growth factor 23 (FGF23)
Molecular Target Fibroblast growth factor 23 (FGF23)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard Indication Musculoskeletal (unspecified)
Indication DetailsTreat tumor-induced osteomalacia (TIO); Treat X-linked hypophosphatemia (XLH)
Regulatory Designation U.S. - Fast Track (Treat X-linked hypophosphatemia (XLH));
U.S. - Orphan Drug (Treat X-linked hypophosphatemia (XLH));
EU - Orphan Drug (Treat X-linked hypophosphatemia (XLH))
Partner Ultragenyx Pharmaceutical Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today